Cardiovascular Outcomes Among Persons with HIV and Nonalcoholic Fatty Liver Disease

Overview

Journal AIDS

Specialty Infectious Diseases

Date 2023 Oct 12

PMID 37822712

Authors

Sepiso K Masenga

Lweendo Muchaili

Benson M Hamooya

Affiliations

Soon will be listed here.

Citing Articles

The effect of ertugliflozin in patients with nonalcoholic fatty liver disease associated with type 2 diabetes mellitus: A randomized controlled trial.

Khaliq A, Badshah H, Shah Y, Rehman I, Khan K, Ming L Medicine (Baltimore). 2024; 103(45):e40356.

PMID: 39533572 PMC: 11556963. DOI: 10.1097/MD.0000000000040356.

References

Masenga S, Hamooya B, Nzala S, Kwenda G, Heimburger D, Mutale W . Patho-immune Mechanisms of Hypertension in HIV: a Systematic and Thematic Review. Curr Hypertens Rep. 2019; 21(7):56. PMC: 6548744. DOI: 10.1007/s11906-019-0956-5. View

Feinstein M . HIV, Subclinical Cardiovascular Disease, and Clinical Progression: Insights From Immunologic Heterogeneity. JAMA. 2022; 328(10):931-932. PMC: 9753140. DOI: 10.1001/jama.2022.15226. View

Krahn T, Martel M, Sapir-Pichhadze R, Kronfli N, Falutz J, Guaraldi G . Nonalcoholic Fatty Liver Disease and the Development of Metabolic Comorbid Conditions in Patients With Human Immunodeficiency Virus Infection. J Infect Dis. 2020; 222(5):787-797. DOI: 10.1093/infdis/jiaa170. View

Parker E, Judge M, Macete E, Nhampossa T, Dorward J, Langa D . HIV infection in Eastern and Southern Africa: Highest burden, largest challenges, greatest potential. South Afr J HIV Med. 2021; 22(1):1237. PMC: 8182467. DOI: 10.4102/sajhivmed.v22i1.1237. View

Barnes R, Lacson J, Bahrami H . HIV Infection and Risk of Cardiovascular Diseases Beyond Coronary Artery Disease. Curr Atheroscler Rep. 2017; 19(5):20. PMC: 6066370. DOI: 10.1007/s11883-017-0652-3. View

Kim D, Kim W . Nonobese Fatty Liver Disease. Clin Gastroenterol Hepatol. 2016; 15(4):474-485. DOI: 10.1016/j.cgh.2016.08.028. View

Hsue P, Waters D . Time to Recognize HIV Infection as a Major Cardiovascular Risk Factor. Circulation. 2018; 138(11):1113-1115. PMC: 8063774. DOI: 10.1161/CIRCULATIONAHA.118.036211. View

Benedict M, Zhang X . Non-alcoholic fatty liver disease: An expanded review. World J Hepatol. 2017; 9(16):715-732. PMC: 5468341. DOI: 10.4254/wjh.v9.i16.715. View

Win S, Than T, Zhang J, Oo C, Min R, Kaplowitz N . New insights into the role and mechanism of c-Jun-N-terminal kinase signaling in the pathobiology of liver diseases. Hepatology. 2017; 67(5):2013-2024. PMC: 5906137. DOI: 10.1002/hep.29689. View

10.

Ramadan M, Russo V, Nigro G, Durante-Mangoni E, Zampino R . Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective. J Clin Med. 2021; 10(8). PMC: 8068259. DOI: 10.3390/jcm10081569. View

11.

van Welzen B, Mudrikova T, El Idrissi A, Hoepelman A, Arends J . A Review of Non-Alcoholic Fatty Liver Disease in HIV-Infected Patients: The Next Big Thing?. Infect Dis Ther. 2019; 8(1):33-50. PMC: 6374241. DOI: 10.1007/s40121-018-0229-7. View

12.

Niederseer D, Wernly B, Aigner E, Stickel F, Datz C . NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations. J Clin Med. 2021; 10(3). PMC: 7865665. DOI: 10.3390/jcm10030467. View

13.

Targher G, Byrne C, Tilg H . NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020; 69(9):1691-1705. DOI: 10.1136/gutjnl-2020-320622. View

14.

Hadigan C, Meigs J, Corcoran C, Rietschel P, Piecuch S, Basgoz N . Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis. 2000; 32(1):130-9. DOI: 10.1086/317541. View

15.

Luedde T, Schwabe R . NF-κB in the liver--linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2011; 8(2):108-18. PMC: 3295539. DOI: 10.1038/nrgastro.2010.213. View

16.

Krishnan A, Woreta T, Sims O, Hamilton J, Potter J, Alqahtani S . Impact of nonalcoholic fatty liver disease on clinical outcomes in patients with COVID-19 among persons living with HIV: A multicenter research network study. J Infect Public Health. 2023; 16(5):673-679. PMC: 9922673. DOI: 10.1016/j.jiph.2023.02.008. View

17.

Kabarra K, Golabi P, Younossi Z . Nonalcoholic steatohepatitis: global impact and clinical consequences. Endocr Connect. 2021; 10(10):R240-R247. PMC: 8558888. DOI: 10.1530/EC-21-0048. View

18.

Machluf Y, Tal O, Navon A, Chaiter Y . From Population Databases to Research and Informed Health Decisions and Policy. Front Public Health. 2017; 5:230. PMC: 5613084. DOI: 10.3389/fpubh.2017.00230. View

19.

Kaplan A, Simon T, Henson J, Wang T, Zheng H, Osganian S . Brief Report: Relationship Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease in Persons With HIV. J Acquir Immune Defic Syndr. 2020; 84(4):400-404. PMC: 10462389. DOI: 10.1097/QAI.0000000000002359. View

20.

Masenga S, Elijovich F, Koethe J, Hamooya B, Heimburger D, Munsaka S . Hypertension and Metabolic Syndrome in Persons with HIV. Curr Hypertens Rep. 2020; 22(10):78. PMC: 7467859. DOI: 10.1007/s11906-020-01089-3. View